Remarkably, in vivo administration of the NLRP3 inhibitor, MCC950, repressed lymphoma expansion and reduced the concentrations of IL-1β and IL-18, consequently downregulating PD-L1 [25]. This evidence concerns the gene IL18 and lymphoma.